GeneDx Holdings Corp. reports $114.4 million revenue, up 11% year-over-year, with 32% genome volume growth, and reiterates full year 2026 revenue guidance of $475 to $490 million. This beats the consensus estimate, and shares rise 7.56% today.

Key Highlights

  • GeneDx Holdings Corp. reports 32% year-over-year genome volume growth, with genome test result volume growth
  • Adjusted gross margin of 70% and adjusted net income in Q2 2026
  • Blackstone agrees to provide additional funding to GeneDx Holdings Corp.

Q2 2026 Results

GeneDx Holdings Corp. (NASDAQ: WGS) reports $114.4 million revenue for the second quarter of 2026, an increase year-over-year, driven by growth in genome test revenue. The company's genome volume growth was 32% year-over-year, with a significant increase in test result volume. This strong performance is a positive sign for investors.

Revenue Growth

The revenue growth was driven by the increase in genome test revenue. The adjusted gross margin was 70%, and the company's operating expenses represented 70% of revenue.

Blackstone Investment

This investment is a significant vote of confidence in the company's growth prospects, and the additional funding will help to support its ongoing operations and expansion plans. The company's pro forma cash position following this transaction provides a strong foundation for future growth.

Future Outlook

The next catalyst for the stock will be the company's conference call, where management will provide further guidance on the company's performance and outlook. With the company's ability to execute on its growth plans and deliver on its revenue guidance, investors will be watching closely for any signs of future growth. The company's growth prospects in the genome testing sector are favorable, driven by increasing demand for genetic testing and analysis.

GeneDx Holdings Corp.'s position in this sector, combined with its strong revenue growth and profitability, make it an attractive investment opportunity.

Analysis based on the Form 8-K filed 3 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.